U.S. markets closed

Electromedical Technologies, Inc. (EMED)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.3300-0.0060 (-1.79%)
At close: 3:42PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.3360
Open0.3400
BidN/A x N/A
AskN/A x N/A
Day's Range0.2860 - 0.3400
52 Week Range0.2530 - 0.7300
Volume122,390
Avg. Volume83,691
Market Cap9.507M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Electromedical Technologies Secures Funding for Product Expansion
    PR Newswire

    Electromedical Technologies Secures Funding for Product Expansion

    Electromedical Technologies, Inc. (OTCQB: EMED) (the "Company"), a pioneer in the development and manufacturing of bioelectronic devices, including the FDA cleared WellnessPro+, is pleased to announce that it has secured a $1 million investment by a fund managed by Yorkville Advisors Global, LP to complete prototype production of its WellnessPlus POD, a critical step in the Company's product development and expansion plans. Further details of the financing can be found in Electromedical Technologies' recent 8-K filing.

  • Electromedical’s Annual Cyber Sale of Flagship Pain Relief Electrotherapy Device Set to Drive Year-End Revenue
    GlobeNewswire

    Electromedical’s Annual Cyber Sale of Flagship Pain Relief Electrotherapy Device Set to Drive Year-End Revenue

    \- Company routinely enjoys end-of-year bump in sales \- Early indications suggest solid demand for highly effective pain relief device \- Current cyber special offering $300 discount runs through December 23rd\- With $4.2 million in inventory, Electromedical setting stage for major sales aheadSCOTTSDALE, Ariz., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Electromedical Technologies, Inc. (OTCQB: EMED) (the "Company"), a pioneer in the development and manufacturing of bioelectronic devices, including the FDA cleared WellnessPro+, is pleased to announce that its annual product special offer is generating solid demand and interest, which is typical of this holiday season cyber campaign. The current cyber sale includes a $300 discount off of the flagship WellnessPro+ price and continues through December 23, 2020.Electromedical Technologies has roughly $4.2 million of the product in inventory and management plans to sell most of its units during this campaign and through future sales events. These initiatives are ahead of the prospective launch of the WellnessPlus POD, which is currently under development. The WellnessPlus POD is positioned as a new, professional grade device for retail customers that is smaller, has more features, and is less expensive than existing commercial models.Matthew Wolfson, Founder and CEO of EMED, commented, “Every year we launch our Cyber Monday promo, we enjoy a spike in sales. Demand and interest remain solid thus far this holiday season, aided by a meaningful $300 device discount. With over 10,000 products sold over the years, we are pleased to have helped our customers with relief from their chronic pain through electrotherapy and look forward to providing comfort and relief to many more ahead. We plan to engage in various campaigns to sell most of our remaining products as we develop our new WellnessPlus POD and prepare for its prospective launch late next year.”About Electromedical TechnologiesHeadquartered in Scottsdale Arizona, Electromedical Technologies, Inc. is a commercial stage, FDA cleared, bioelectronic medical device manufacturing company initially focused on the treatment of various chronic, acute, intractable, and post-operative pain conditions. Through university collaboration agreements the company is working to develop a comprehensive research program in defining the effects of electro-modulation on the human body by studying the impacts of electrical fields in cell signaling and effects on virus assembly and immune responses with the goal of improving human wellbeing. The company’s current cleared product indications are for chronic acute post traumatic and post-operative, intractable pain relief.Our animal studies do not involve any human testing, and are not related to our current products. We are conducting this research to augment and advance the science of electro-modulation in healthcare. The United States Food and Drug Administration has not reviewed or approved our animal research studiesFor more information, visit www.electromedtech.com.Safe Harbor StatementThis release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.Corporate Contact:Electromedical Technologies, Inc. Matthew Wolfson Tel: 1.888.880.7888 email: ceo@electromedtech.com https://electromedtech.com

  • New Electromedical Technologies Strategic Partner to Aid in Driving Awareness and Sales
    GlobeNewswire

    New Electromedical Technologies Strategic Partner to Aid in Driving Awareness and Sales

    * High profile firm WireBuzz boasts relationships with Fortune 500 firms and nation’s top health care companies * Industry leading digital marketing agency renowned for driving awareness and online business * WireBuzz poised to aid Electromedical Technologies in onboarding new distributors and customers SCOTTSDALE, Ariz., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Electromedical Technologies, Inc. (OTCQB: EMED ) (the "Company"), a pioneer in the development and manufacturing of bioelectronic devices, including the FDA cleared WellnessPro+, is pleased to announce its new strategic partnership with WireBuzz, LLC (www.wirebuzz.com), an award-winning video and web design agency. The Company elected to work with WireBuzz based upon its renowned reputation for content production, advanced marketing, and specifically, its impressive online customer conversion capabilities.In its first stage,  WireBuzz is revamping the Company website to emulate the style and success of sites for WireBuzz Fortune 500 clients, and others. Future steps include the production of new marketing tools including video content for use by Electromedical Technologies’ distributors and influencers. WireBuzz produces more than 3,000 videos each year, which are extremely powerful and effective visual sales resources. The use of online content marketing is one of the most successful sales methods in the current COVID-19 environment and is expected to be a major driver of product sales, going forward.In addition to its video marketing capabilities, WireBuzz also provides strategy and messaging development, sales process optimization and automation, and diverse content marketing campaigns.Matthew Wolfson, Founder and CEO of EMED, commented, “We are thrilled to be working with the WireBuzz team. Their reputation as effective customer conversion specialists through video production and marketing made it a no-brainer. Plus, we believe that the upgrading of our website in a style that emulates the top health care device companies sets the stage for Electromedical Technologies to reach that upper tier, going forward. The new site will go live later this month. In addition, we look forward to sharing new videos and testimonials with our customers, shareholders, and prospective new customers seeking an effective, non-invasive product to treat chronic pain. With over $4 million in inventory available for sale, upcoming campaigns could drive product sales as we head into 2021.”About Electromedical TechnologiesHeadquartered in Scottsdale Arizona, Electromedical Technologies, Inc. is a commercial stage, FDA cleared, bioelectronic medical device manufacturing company initially focused on the treatment of various chronic, acute, intractable, and post-operative pain conditions. Through university collaboration agreements the company is working to develop a comprehensive research program in defining the effects of electro-modulation on the human body by studying the impacts of electrical fields in cell signaling and effects on virus assembly and immune responses with the goal of improving human wellbeing. The company’s current cleared product indications are for chronic acute post traumatic and post-operative, intractable pain relief.Our animal studies do not involve any human testing, and are not related to our current products. We are conducting this research to augment and advance the science of electro-modulation in healthcare. The United States Food and Drug Administration has not reviewed or approved our animal research studiesFor more information, visit www.electromedtech.com.Safe Harbor StatementThis release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.Corporate Contact:Electromedical Technologies, Inc. Matthew Wolfson Tel: 1.888.880.7888 email: ceo@electromedtech.com https://electromedtech.com